Photoelectrocatalytic reduction of CO2 to fuels has great potential for reducing anthropogenic CO2 emissions and also lessening our dependence on fossil fuel energy.Herein,we report the successful development of a nov...Photoelectrocatalytic reduction of CO2 to fuels has great potential for reducing anthropogenic CO2 emissions and also lessening our dependence on fossil fuel energy.Herein,we report the successful development of a novel photoelectrocatalytic catalyst for the selective reduction of CO2 to methanol,comprising a copper catalyst modified with flower-like cerium oxide nanoparticles(CeO2 NPs)(a n-type semiconductor)and copper oxide nanoparticles(CuO NPs)(a p-type semiconductor).At an applied potential of−1.0 V(vs SCE)under visible light irradiation,the CeO2 NPs/CuO NPs/Cu catalyst yielded methanol at a rate of 3.44μmol cm^−2 h^−1,which was approximately five times higher than that of a CuO NPs/Cu catalyst(0.67μmol cm^−2 h^−1).The carrier concentration increased by^108 times when the flower-like CeO2 NPs were deposited on the CuO NPs/Cu catalyst,due to synergistic transfer of photoexcited electrons from the conduction band of CuO to that of CeO2,which enhanced both photocatalytic and photoelectrocatalytic CO2 reduction on the CeO2 NPs.The facile migration of photoexcited electrons and holes across the p–n heterojunction that formed between the CeO2 and CuO components was thus critical to excellent light-induced CO2 reduction properties of the CeO2 NPs/CuO NPs/Cu catalyst.Results encourage the wider application of composite semiconductor electrodes in carbon dioxide reduction.展开更多
The combined effect of gallic acid (3,4,5-trihydroxy benzoic acid;GA;50 mg kg^(-1) i.p.) and propolis (200 mg kg^(-1)p.o.)was evaluated against beryllium-induced biochemical and morphological alterations in the liver ...The combined effect of gallic acid (3,4,5-trihydroxy benzoic acid;GA;50 mg kg^(-1) i.p.) and propolis (200 mg kg^(-1)p.o.)was evaluated against beryllium-induced biochemical and morphological alterations in the liver and kidney. Femalealbino rats were exposed to beryllium nitrate (1 mg kg^(-1)i.p.) daily for 28 days followed by treatment with the abovementioned therapeutic agents either individually or in combination for five consecutive days. Exposure to berylliumincreased its concentration in the serum, liver and kidney and caused significant alterations in cytochrome P450enzymes, microsomal lipid peroxidation and protein contents. Beryllium administration significantly altered theaspartate aminotransaminase, alanine aminotransaminase, lactate dehydrogenase, -glutamyl transpeptidase,bilirubin, creatinine and urea in serum, and the activity of acid phosphatase, alkaline phosphatase, adenosinetriphosphatase, glucose-6-phophatase and succinic dehydrogenase, triglycerides, cholesterol, protein contents,glycogen contents, lipid peroxidation and glutathione level in the liver and kidney. Beryllium exposure inducedsevere alterations in hepatorenal morphology, revealing its toxic consequences at a cellular level. Individual administrationof GA and propolis reduced the effects on the studied parameters to a degree. Interestingly, GA in conjunctionwith propolis reversed the alterations in all of the variables examined, highlighting the beneficial effects ofcombined therapy over monotherapy in the alleviation of beryllium-induced systemic toxicity.展开更多
Cancer is a major global health issue.Effective therapeutic strategies can prolong patients’survival and reduce the costs of treatment.Drug repurposing,which identifies new therapeutic uses for approved drugs,is a pr...Cancer is a major global health issue.Effective therapeutic strategies can prolong patients’survival and reduce the costs of treatment.Drug repurposing,which identifies new therapeutic uses for approved drugs,is a promising approach with the advantages of reducing research costs,shortening development time,and increasing efficiency and safety.Disulfiram(DSF),a Food and Drug Administration(FDA)-approved drug used to treat chronic alcoholism,has a great potential as an anticancer drug by targeting diverse human malignancies.Several studies show the antitumor effects of DSF,particularly the combination of DSF and copper(DSF/Cu),on a wide range of cancers such as glioblastoma(GBM),breast cancer,liver cancer,pancreatic cancer,and melanoma.In this review,we summarize the antitumor mechanisms of DSF/Cu,including induction of intracellular reactive oxygen species(ROS)and various cell death signaling pathways,and inhibition of proteasome activity,as well as inhibition of nuclear factor-kappa B(NF-κB)signaling.Furthermore,we highlight the ability of DSF/Cu to target cancer stem cells(CSCs),which provides a new approach to prevent tumor recurrence and metastasis.Strikingly,DSF/Cu inhibits several molecular targets associated with drug resistance,and therefore it is becoming a novel option to increase the sensitivity of chemo-resistant and radio-resistant patients.Studies of DSF/Cu may shed light on its improved application to clinical tumor treatment.展开更多
基金financially supported by the National Natural Science Foundation of China(21802089)Natural Science Foundation of Shandong Province(ZR2019BB015)+5 种基金The Science and Technology Plan of Shandong Province Colleges and Universities under Grant(No.J14LC16)the Natural Science Foundation of Shandong Province under Grant(No.ZR2017MB018)funding support from the Shandong Province Double Hundred Talents Program for Foreign Expertsthe Energy Education Trust of New Zealandthe Dodd Walls Centre for Photonic and Quantum Technologiesthe Mac Diarmid Institute for Advanced Materials and Nanotechnology
文摘Photoelectrocatalytic reduction of CO2 to fuels has great potential for reducing anthropogenic CO2 emissions and also lessening our dependence on fossil fuel energy.Herein,we report the successful development of a novel photoelectrocatalytic catalyst for the selective reduction of CO2 to methanol,comprising a copper catalyst modified with flower-like cerium oxide nanoparticles(CeO2 NPs)(a n-type semiconductor)and copper oxide nanoparticles(CuO NPs)(a p-type semiconductor).At an applied potential of−1.0 V(vs SCE)under visible light irradiation,the CeO2 NPs/CuO NPs/Cu catalyst yielded methanol at a rate of 3.44μmol cm^−2 h^−1,which was approximately five times higher than that of a CuO NPs/Cu catalyst(0.67μmol cm^−2 h^−1).The carrier concentration increased by^108 times when the flower-like CeO2 NPs were deposited on the CuO NPs/Cu catalyst,due to synergistic transfer of photoexcited electrons from the conduction band of CuO to that of CeO2,which enhanced both photocatalytic and photoelectrocatalytic CO2 reduction on the CeO2 NPs.The facile migration of photoexcited electrons and holes across the p–n heterojunction that formed between the CeO2 and CuO components was thus critical to excellent light-induced CO2 reduction properties of the CeO2 NPs/CuO NPs/Cu catalyst.Results encourage the wider application of composite semiconductor electrodes in carbon dioxide reduction.
文摘The combined effect of gallic acid (3,4,5-trihydroxy benzoic acid;GA;50 mg kg^(-1) i.p.) and propolis (200 mg kg^(-1)p.o.)was evaluated against beryllium-induced biochemical and morphological alterations in the liver and kidney. Femalealbino rats were exposed to beryllium nitrate (1 mg kg^(-1)i.p.) daily for 28 days followed by treatment with the abovementioned therapeutic agents either individually or in combination for five consecutive days. Exposure to berylliumincreased its concentration in the serum, liver and kidney and caused significant alterations in cytochrome P450enzymes, microsomal lipid peroxidation and protein contents. Beryllium administration significantly altered theaspartate aminotransaminase, alanine aminotransaminase, lactate dehydrogenase, -glutamyl transpeptidase,bilirubin, creatinine and urea in serum, and the activity of acid phosphatase, alkaline phosphatase, adenosinetriphosphatase, glucose-6-phophatase and succinic dehydrogenase, triglycerides, cholesterol, protein contents,glycogen contents, lipid peroxidation and glutathione level in the liver and kidney. Beryllium exposure inducedsevere alterations in hepatorenal morphology, revealing its toxic consequences at a cellular level. Individual administrationof GA and propolis reduced the effects on the studied parameters to a degree. Interestingly, GA in conjunctionwith propolis reversed the alterations in all of the variables examined, highlighting the beneficial effects ofcombined therapy over monotherapy in the alleviation of beryllium-induced systemic toxicity.
基金supported by grants from the Undergraduate Research and Innovation Project of University of South China(Nos.X202110555528,S202210555245,and X202210555136)
文摘Cancer is a major global health issue.Effective therapeutic strategies can prolong patients’survival and reduce the costs of treatment.Drug repurposing,which identifies new therapeutic uses for approved drugs,is a promising approach with the advantages of reducing research costs,shortening development time,and increasing efficiency and safety.Disulfiram(DSF),a Food and Drug Administration(FDA)-approved drug used to treat chronic alcoholism,has a great potential as an anticancer drug by targeting diverse human malignancies.Several studies show the antitumor effects of DSF,particularly the combination of DSF and copper(DSF/Cu),on a wide range of cancers such as glioblastoma(GBM),breast cancer,liver cancer,pancreatic cancer,and melanoma.In this review,we summarize the antitumor mechanisms of DSF/Cu,including induction of intracellular reactive oxygen species(ROS)and various cell death signaling pathways,and inhibition of proteasome activity,as well as inhibition of nuclear factor-kappa B(NF-κB)signaling.Furthermore,we highlight the ability of DSF/Cu to target cancer stem cells(CSCs),which provides a new approach to prevent tumor recurrence and metastasis.Strikingly,DSF/Cu inhibits several molecular targets associated with drug resistance,and therefore it is becoming a novel option to increase the sensitivity of chemo-resistant and radio-resistant patients.Studies of DSF/Cu may shed light on its improved application to clinical tumor treatment.
